Cantor Fitzgerald Reiterates Overweight Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Cantor Fitzgerald reiterated their overweight rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research report released on Wednesday morning, Benzinga reports. Cantor Fitzgerald currently has a $180.00 price objective on the specialty pharmaceutical company’s stock.

Several other equities analysts have also weighed in on JAZZ. Truist Financial restated a buy rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 20th. Needham & Company LLC restated a buy rating and issued a $220.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 20th. StockNews.com upgraded Jazz Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Tuesday, January 30th. Stifel Nicolaus lifted their price target on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a buy rating in a research note on Friday, March 15th. Finally, Barclays cut their price target on Jazz Pharmaceuticals from $235.00 to $230.00 and set an overweight rating for the company in a research note on Friday, March 1st. Two investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus price target of $195.08.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ opened at $114.08 on Wednesday. The stock has a 50-day simple moving average of $121.66 and a two-hundred day simple moving average of $123.44. The firm has a market capitalization of $7.19 billion, a P/E ratio of 18.64, a PEG ratio of 1.59 and a beta of 0.59. Jazz Pharmaceuticals has a fifty-two week low of $111.25 and a fifty-two week high of $147.45. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.85 and a current ratio of 2.24.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share for the quarter, missing analysts’ consensus estimates of $4.44 by ($0.04). The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1.01 billion. Jazz Pharmaceuticals had a net margin of 10.82% and a return on equity of 31.27%. On average, equities analysts forecast that Jazz Pharmaceuticals will post 16.24 earnings per share for the current year.

Insider Transactions at Jazz Pharmaceuticals

In other news, CAO Patricia Carr sold 1,936 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total transaction of $231,623.04. Following the transaction, the chief accounting officer now directly owns 8,364 shares in the company, valued at approximately $1,000,668.96. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CFO Philip L. Johnson bought 12,000 shares of the stock in a transaction dated Friday, March 1st. The shares were acquired at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the acquisition, the chief financial officer now directly owns 27,932 shares in the company, valued at approximately $3,342,063.80. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Patricia Carr sold 1,936 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total value of $231,623.04. Following the transaction, the chief accounting officer now owns 8,364 shares in the company, valued at $1,000,668.96. The disclosure for this sale can be found here. Insiders own 4.40% of the company’s stock.

Institutional Trading of Jazz Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Jazz Pharmaceuticals by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 6,379,053 shares of the specialty pharmaceutical company’s stock valued at $825,705,000 after buying an additional 29,960 shares during the period. Wellington Management Group LLP raised its position in shares of Jazz Pharmaceuticals by 7.5% during the 1st quarter. Wellington Management Group LLP now owns 2,625,134 shares of the specialty pharmaceutical company’s stock valued at $408,654,000 after buying an additional 184,124 shares during the period. State Street Corp raised its position in shares of Jazz Pharmaceuticals by 1.8% during the 2nd quarter. State Street Corp now owns 2,372,395 shares of the specialty pharmaceutical company’s stock valued at $294,106,000 after buying an additional 42,703 shares during the period. LSV Asset Management raised its position in shares of Jazz Pharmaceuticals by 2.4% during the 3rd quarter. LSV Asset Management now owns 2,372,177 shares of the specialty pharmaceutical company’s stock valued at $307,055,000 after buying an additional 55,630 shares during the period. Finally, FMR LLC raised its position in shares of Jazz Pharmaceuticals by 8.1% during the 3rd quarter. FMR LLC now owns 1,333,129 shares of the specialty pharmaceutical company’s stock valued at $172,560,000 after buying an additional 100,349 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.